PopGen: A virtual human population generator

Toxicology

Volumn 315, Issue 1, 2014, Pages 70-85

  McNally, Kevin ^a   Cotton, Richard ^b   Hogg, Alex ^a   Loizou, George ^a  

^a HEALTH AND SAFETY LABORATORY   (United Kingdom)

^b TDL Ltd   (United Kingdom)

Author keywords

PBPK; Population variability; QIVIVE; Reverse dosimetry; Virtual human population generator

Indexed keywords

AGE; ALGORITHM; ARTICLE; BODY MASS; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HEIGHT; HUMAN; INFORMATION PROCESSING; MONTE CARLO METHOD; ORGAN; POPULATION EXPOSURE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SIMULATION; TISSUES; TOXICITY;

EID: 84890631557     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.07.009     Document Type: Article

References (72)

1. Adler S., et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010. Arch. Toxicol. 2011, 85:367-485.
2. Allen B.C., et al. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal. 2007, 27:947-959.
3. Araujo A.B., et al. Race/ethnic differences in bone mineral density in men. Osteoporos. Int. 2007, 18:943-953.
4. Barter Z.E., et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
5. Basketter D.A., et al. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*. Altex 2012, 29:3-91.
6. Baxter-Jones A.D., et al. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J. Bone Miner. Res. 2011, 26:1729-1739.
7. Bhattacharya S., et al. Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS ONE 2011, 6:e20887.
8. Blaauboer B.J. Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicol. Lett. 2001, 120:111-123.
9. Blaauboer B.J. The necessity of biokinetic information in the interpretation of in vitro toxicity data. ATLA-Altern. Lab. Anim. 2002, 30(Suppl. 2):85-91.
10. Blaauboer B.J. Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment. ATLA-Altern. Lab. Anim. 2003, 31:277-281.
11. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 2003, 138:161-171.
12. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health Part B: Crit. Rev. 2010, 13:242-252.
13. Blaauboer B.J., et al. The integrated use of alternative methods in toxicological risk evaluation: ECVAM integrated testing strategies task force report 1. ATLA-Altern. Lab. Anim. 1999, 27:229-237.
14. Blaauboer B.J., et al. The use of biokinetics and in vitro methods in toxicological risk evaluation. ATLA-Altern. Lab. Anim. 1996, 24:473-497.
15. Bosgra S., et al. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit. Rev. Toxicol. 2012, 42:751-767.
16. Bouvier d'Yvoire M., et al. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda: the report and recommendations of ECVAM workshop 63. ATLA-Altern. Lab. Anim. 2007, 35:661-671.
17. Carpenter C.L., et al. Body fat and body-mass index among a multiethnic sample of college-age men and women. J. Obes. 2013, 2013:7.
18. CDC, 1996. The Third National Health and Nutrition Examination Survey (NHANES III, 1988-94). Statistics (Ed.). National Center for Health, Atlanta, GA.
19. Clark L.H., et al. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 2004, 24:1697-1717.
20. Clewell H.J., et al. Site-specific reference dose for methylmercury for fish-eating populations. Fuel Process. Technol. 2000, 65-66:43-54.
21. Collis T., et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001, 103:820-825.
22. Coppoletta J.M., Wolbach S.B. Body length and organ weights of infants and children: a study of the body length and normal weights of the more important vital organs of the body between birth and twelve years of age. Am. J. Pathol. 1933, 9:55-70.
23. Costeff H. A simple empirical formula for calculating approximate surface area in children. Arch. Dis. Child. 1966, 41:681-683.
24. de la Grandmaison G.L., et al. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci. Int. 2001, 119:149-154.
25. DeJongh J., et al. An integrated approach to the prediction of systemic toxicity using computer-based biokinetic models and biological in vitro test methods: overview of a prevalidation study based on the ECITTS Project. Toxicol. In Vitro 1999, 13:549-554.
26. Department of Health, 2010a. Health Survey for England. http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/index.htm.
27. Department of Health, 2010b. National Diet and Nutrition Survey. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_128166.
28. Franks S.J., et al. Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol. Toxicol. Lett. 2006, 162:164-173.
29. Gelman A., et al. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 1996, 91:1400-1412.
30. Georgopoulos P.G., et al. Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models. J. Exp. Anal. Environ. Epidemiol. 1994, 4:309-328.
31. Heinemann A., et al. Standard liver volume in the Caucasian population. Liver Transpl. Surg. 1999, 5:366-368.
32. Heymsfield S.B., et al. Scaling of human body composition to stature: new insights into body mass index. Am. J. Clin. Nutr. 2007, 86:82-91.
33. Howgate E.M., et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006, 36:473-497.
34. ICRP, 2003. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon.
35. Jamei M., et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 2009, 24:53-75.
36. Jamei M., et al. The Simcyp((R)) population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 2009, 5:211-223.
37. Janssen I., et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J. Appl. Physiol. 2000, 89:81-88.
38. Jones K., Cocker J. A human exposure study to investigate biological monitoring methods for 2-butoxyethanol. Biomarkers 2003, 8:360-370.
39. Jongeneelen F.J., Berge W.F. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. Ann. Occup. Hyg. 2011, 55:841-864.
40. Judson, R.S., et al., 2009. In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 118.
41. Kavlock R. The future of toxicity testing-the NRC vision and the EPA's ToxCast program national center for computational toxicology. Neurotoxicol. Teratol. 2009, 31:237.
42. Kim Y.-S., et al. Statistical Analysis for Organ Weights in Korean Adult Autopsies. Korean J. Anat. 2009, 42:219-224.
43. Krewski D., et al. New directions in toxicity testing. Annu. Rev. Public Health 2011, 32:161-178.
44. Levitt D.G., et al. Physiological models of body composition and human obesity. Nutr. Metab. (Lond.) 2007, 4:19.
45. Loizou, G.D., Hogg, A. (2011). MEGen: a physiologically based pharmacokinetic model generator. Fron. Pharmacol.: Pred. Toxicity 2 Article 56, 51-14.
46. Loizou G.D., et al. Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. Toxicol. Sci. 1999, 48:170-179.
47. Loizou G.D., et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul. Toxicol. Pharm. 2008, 50:400-411.
48. Looker A.C., et al. Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos. Int. 2009, 20:1141-1149.
49. Lyons M.A., et al. Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environ. Health Perspect. 2008, 116:1040-1046.
50. McLanahan E.D., et al. Physiologically based pharmacokinetic model use in risk assessment-why being published is not enough. Toxicol. Sci. 2012, 126:5-15.
51. McNally K., et al. Reconstruction of exposure to m-xylene from human biomonitoring data using PBPK modelling, Bayesian inference, and Markov Chain Monte Carlo simulation. J. Toxicol. 2012, 2012:18.
52. McNally K., et al. A workflow for global sensitivity analysis of PBPK models. Front. Pharmacol.: Pred. Toxicity 2011, 2. Article 31, 31-21.
53. Moore F.D., et al. The Body Cell Mass and its Supporting Environment 1963, WB Saunders, Philadelphia, PA.
54. Mosquin P.L., et al. Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple biomarkers. J. Expos. Sci. Environ. Epidemiol. 2009, 19:284-297.
55. Narongchai P., Narongchai S. Study of the normal internal organ weights in Thai population. J. Med. Assoc. Thai. 2008, 91:747-753.
56. NRC (Ed.), 2007. Toxicity Testing in the Twenty-First Century: A Vision and a Strategy. (Committee on Toxicity and Assessment of Environmental Agents). National Research Council, Washington, DC.
57. Ogiu N., et al. A statistical analysis of the internal organ weights of normal Japanese people. Health Phys. 1997, 72:368-383.
58. P3M™ Database, 2003. Physiological Parameters for PBPK Modeling™ Version 1.3 (P3M™). The Lifeline Group. http://www.thelifelinegroup.org/p3m/index.htm.
59. Price P.S., et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003, 33:469-503.
60. R Development Core Team, 2010. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, http://www.r-project.org/.
61. Rowland M., et al. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). Am. Assoc. Pharma. Sci. 2004, 6:1-12.
62. Roy A., Georgopoulos P.G. Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models. J. Expos. Anal. Environ. Epidemiol. 1998, 8:407-422.
63. Shiran M.R., et al. Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 2006, 36:567-580.
64. Sohn M.D., et al. Reconstructing population exposures from dose biomarkers: inhalation of trichloroethylene (TCE) as a case study. J. Expos. Anal. Environ. Epidemiol. 2004, 14:204-213.
65. Thompson C.M., et al. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J. Toxicol. Environ. Health B: Crit. Rev. 2009, 12:1-24.
66. WHO, 2010. Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment: Harmonization Project Document No. 9. WHO, Geneva.
67. Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis. Springer, New York, http://www.r-project.org/.
68. Wilkin L.D., et al. Racial/ethnic differences in bone mineral density of young adults. Int. J. Exer. Sci. 2010, 3:197-205.
69. Willmann S., et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 2007, 34:401-431.
70. Wilmore J.H., et al. Body composition. Phys. Sports Med. 1986, 14:144-162.
71. Yoon M., et al. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 2012.
72. Zhao P., et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 2011, 89:259-267.